Communiqués Natera, Inc.

Actions

NTRA

US6323071042

Installations et services en soins de santé

Marché Fermé - Nasdaq 22:00:00 07/10/2026			Varia. 5j.	Varia. 1 janv.
395,56 ^USD	-1,27%		-4,57%	+72,67%

21:20	Natera, Inc. annonce l’inclusion des premiers patients dans un nouvel essai guidé par Signatera dans le mélanome	CI
14:26	L’étude de Natera sur Signatera visant à détecter plus tôt les cancers de la peau commence à inclure des patients	MT

Communiqués

16:09	Natera, Inc. - New Signatera Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists	AQ
14:02	Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma	BU
06/10	Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech's Oral Selective Estrogen Receptor Degrader	AQ
06/10	New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists	BU
05/10	Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer	BU
23/09	Natera, Inc. - Signatera Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer	AQ
22/09	Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer	BU
18/09	Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM	BU
01/09	New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma	BU
31/08	Natera and Susan G. Komen Announce National Partnership to Accelerate Progress against Breast Cancer	AQ
28/08	Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer	BU
27/08	Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™	BU
13/08	Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude in Advanced Skin Cancers	AQ
12/08	Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers	BU
07/08	Natera : Q2 2026 Earnings Presentation	PU
06/08	Natera: Q2 Earnings Snapshot	AQ
06/08	Natera Reports Second Quarter 2026 Financial Results	BU
05/08	Natera Submits Signatera™ to Japan’s PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer	BU
30/07	Natera to Report its Second Quarter Results on August 6, 2026	BU
22/07	Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study	BU
17/07	Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio	BU
09/07	Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers	BU
06/07	Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer	BU
29/06	Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer	BU
25/06	Natera, Inc. - Signatera Receives Regulatory Approval in Japan for Colorectal Cancer	AQ